Qureator’s Microphysiological Systems (MPS) known as Curiochips, are designed for recapitulating the complexity of tissue microenvironments, thus providing ideal microscale 3D cell culture conditions. The company was formerly known as Curiochips and changed its name to Qureator in 2020. Qureator is headquartered in San Diego, California. Qureator, a biomedical company, focuses on the development of novel platforms and high-throughput disease models for precision medicine in areas of high unmet medical needs. The company provides Microphysiological Systems (MPS) which enable investigators to perform co-cultures of multiple cell types in 3D and high-throughput screenings for biomedical research and drug discovery. The company also offers a variety of patient-derived in vitro models in organs-on-chips which closely recapitulate the pathophysiology of diseases. These models can be efficiently applicable to target identification and compound screening, especially in the areas of fibrosis, oncology, angiogenesis, ocular disease and vasculogenesis. The company has multiple collaborations with pharmaceutical companies and academic institutions for assay development, safety evaluation, and drug discovery. Conventional preclinical testing has faced a problem in that the results do not correctly reflect and anticipate the drug effect on the human body, which results in significantly increased cost and time of drug discovery and development. Academia and industries have endeavored to solve this mismatched preclinical testing for human drug treatments over the last several decades. As a result, several in vitro testing platforms such as 3D cell culture, organoid, bioprinting, Microphysiological Systems (MPS) and Organ-on-a-Chip technologies have been developed. Although these approaches have comparative advantages toward specific purposes, we concluded that the Organ-on-a-Chip technology is the most appropriate one to mimic human model systems and evaluate drug candidates.